AbbVie stock heads into the open near recent highs

AbbVie stock closed at USD 262.51 on the NYSE on September 16, 2026, after a slight decline of 0.20% from the prior session, according to recent market data compilations. Compared with its 52-week high near USD 267, the stock finished the last session within a few dollars of that peak, underscoring its strong run in recent months.

September 16, 2026 in numbers

AbbVie Inc. (ISIN US00287Y1091, NYSE: ABBV) ended the September 16, 2026 NYSE session at around USD 262.51, with intraday trading keeping the shares within a narrow range close to their 52-week high, as reflected in quote overviews from major financial portals. Per these data points, AbbVie has delivered a robust double-digit total return over the past year, with the stock’s current level only a few percent below the 52-week peak, while the broader S&P 500 health care segment has advanced more moderately over the same period. Recent commentary highlighted that AbbVie’s adjusted earnings per share of USD 3.65 for the second quarter of 2026 came in slightly above its own guidance midpoint, offering support for the share price as investors reassessed its cash generation capacity, as noted by Tikr. In a separate assessment, Yahoo Finance described AbbVie’s recent share price around USD 262.51 as reflecting strong confidence in its ability to convert its current drug portfolio and pipeline into future cash flows, which has helped underpin the stock near its recent highs.

Today’s drivers and events

Today, September 17, 2026, AbbVie does not have a widely flagged quarterly earnings release, but investors continue to weigh the implications of its recent earnings beat and guidance commentary ahead of the US opening bell, as summarized by Tikr. Broader sector sentiment may also influence AbbVie’s trading today, with health care benchmarks and large peers providing context for how far AbbVie can sustain its premium relative valuation and proximity to its 52-week high as the new session begins.